Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
In: The Journal of investigative dermatology, Jg. 143 (2023-08-01), Heft 8
Online
academicJournal
- 1388 - 1396
Cutaneous neurofibromas (cNFs) are benign tumors of the skin that affect >95% of adults with neurofibromatosis type 1. Despite their benign histology, cNFs can significantly impact QOL due to disfigurement, pain, and pruritus. There are no approved therapies for cNFs. Existing treatments are limited to surgery or laser-based treatments that have had mixed success and cannot be readily applied to a large number of tumors. We review cNF treatment options that are currently available and under investigation, discuss the regulatory considerations specific to cNFs, and propose strategies to improve cNF clinical trial design and standardize clinical trial endpoints.
| Titel: |
Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
|
|---|---|
| Autor/in / Beteiligte Person: | Ly, Ina ; Romo, Carlos G ; Gottesman, Sally ; Kelly, Kristen M ; Kornacki, Deanna ; York, Zachary ; Lee, Sang Y ; Rhodes, Steven D ; Staedtke, Verena ; Steensma, Matthew R ; Blakeley, Jaishri O ; Wolkenstein, Pierre |
| Link: | |
| Zeitschrift: | The Journal of investigative dermatology, Jg. 143 (2023-08-01), Heft 8 |
| Veröffentlichung: | eScholarship, University of California, 2023 |
| Medientyp: | academicJournal |
| Umfang: | 1388 - 1396 |
| Schlagwort: |
|
| Sonstiges: |
|